Obesity’s newest treatment that works

by | Oct 13, 2024 | Uncategorized | 0 comments

By Obesity

Obesity’s newest treatment that works

One of the newest and most promising treatments for obesity is semaglutide, which is marketed under brand names like Wegovy and Ozempic. It belongs to a class of medications called GLP-1 receptor agonists (glucagon-like peptide-1 receptor agonists). Initially developed for treating type 2 diabetes, it has shown significant effectiveness in weight loss and was approved by the FDA for chronic weight management.

How Semaglutide Works:

  • Mimics GLP-1 hormone: Semaglutide mimics a natural hormone (GLP-1) that is involved in appetite regulation. It helps people feel fuller for longer, thereby reducing hunger and calorie intake.
  • Slows down gastric emptying: It delays the time it takes for food to leave the stomach, prolonging the sensation of fullness.
  • Reduces cravings: The medication also impacts brain pathways related to cravings and hunger, making it easier to stick to a lower-calorie diet.

Clinical Effectiveness:

In clinical trials, patients taking semaglutide for obesity management lost an average of 12-15% of their body weight over a 68-week period, which is significantly more than other weight loss medications currently available. Some patients even lost up to 20% of their body weight when combined with lifestyle changes like diet and exercise.

Administration:

  • Semaglutide for weight loss is administered via once-weekly injections.
  • It’s recommended as part of a comprehensive weight management program that includes diet and physical activity.

Other Emerging Treatments:

  1. Tirzepatide (Mounjaro): A dual-acting GLP-1 and GIP receptor agonist that also shows promise in promoting significant weight loss. Early studies suggest it may be even more effective than semaglutide.
  2. Setmelanotide (Imcivree): Approved for rare genetic disorders associated with obesity, this medication targets pathways in the brain related to hunger and fullness.
  3. Orforglipron: An oral GLP-1 receptor agonist currently in development. Unlike semaglutide, this drug is taken orally, which may be a more convenient option for some patients in the future.

Lifestyle-Based Therapies:

In addition to medication, metabolic surgery (e.g., bariatric surgery) continues to be an effective option for those with severe obesity, and newer forms of endoscopic bariatric therapies are also emerging.

Considerations and Side Effects:

While semaglutide is generally well-tolerated, common side effects include nausea, vomiting, diarrhea, and constipation. More severe side effects are rare but include pancreatitis and gallbladder problems.

Semaglutide represents a breakthrough in obesity treatment, providing a highly effective, safe, and scalable solution for many individuals struggling with weight management.

 

4o
You said:
What are GLP-1 agonists? GLP-1 agonists are a class of medications that mainly help manage blood sugar (glucose) levels in people with Type 2 diabetes. Some GLP-1 agonists can also help treat obesity. GLP-1 agonists are most often injectable medications, meaning you inject a liquid medication with a needle and syringe. You give the shots in the fatty tissue just under your skin (subcutaneous injection). Areas of your body you can give the injections include your belly, outer thighs, upper buttocks and the backs of your arms. Other names for this medication class include: Glucagon-like peptide-1 agonists. GLP-1 receptor agonists. Incretin mimetics. GLP-1 analogs. These medications are relatively new. The U.S. Food and Drug Administration (FDA) approved the first GLP-1 agonist (exenatide) in 2005. Researchers are still learning about their other potential uses and benefits. GLP-1 agonists alone can’t treat Type 2 diabetes or obesity. Both conditions require other treatment strategies, like lifestyle and dietary changes. List of GLP-1 agonists GLP-1 agonist medications currently available on the U.S. market include: Dulaglutide (Trulicity®). Exenatide (Byetta®). Exenatide extended-release (Bydureon®). Liraglutide (Victoza®). Lixisenatide (Adlyxin®). Semaglutide injection (Ozempic®). Semaglutide tablets (Rybelsus®). There’s also a similar class of medications called dual GLP-1/GIP receptor agonists. There’s currently one of these medications on the market. It’s called tirzepatide (Mounjaro®). How do GLP-1 agonists work? To understand how GLP-1 agonists work, it helps to understand how the naturally occurring GLP-1 hormone works. GLP-1 is a hormone that your small intestine makes. It has several roles, including: Triggering insulin release from your pancreas: Insulin is an essential hormone that allows your body to use the food you eat for energy. It lowers the amount of glucose (sugar) in your blood. If you don’t have enough insulin, your blood sugar increases, leading to diabetes. Blocking glucagon secretion: Glucagon is a hormone your body uses to raise your blood sugar levels when necessary. So, GLP-1 prevents more glucose from going into your bloodstream. Slowing stomach emptying: Slower digestion means that your body releases less glucose (sugar) from the food you eat into your bloodstream. Increasing how full you feel after eating (satiety): GLP-1 affects areas of your brain that processes hunger and satiety. GLP-1 agonist medications work by mimicking this hormone. In medication terms, an agonist is a manufactured substance that attaches to a cell receptor and causes the same action as the naturally occurring substance. In other words, GLP-1 medications bind to GLP receptors to trigger the effects (or roles) of the GLP-1 hormone. The higher the dose of the GLP-1 agonist, the more extreme the effects. If you have Type 2 diabetes, the medications help manage your blood sugar by triggering your pancreas to release more insulin. The slowed digestion also helps decrease blood sugar spikes. The satiety effect of GLP1-agonists reduces your food intake, appetite and hunger. These combined effects often result in weight loss. When would I need to take a GLP-1 agonist? Healthcare providers prescribe GLP-1 agonists for two conditions: Type 2 diabetes and obesity. GLP-1 agonists for Type 2 diabetes The FDA approves the use of GLP-1 agonists to help manage Type 2 diabetes (T2D). This is because GlP-1 agonists help lower blood sugar levels. There are several other types of diabetes medications, like oral (taken by mouth) medications. One type of oral medication, metformin, is the go-to medication for treating T2D. But your healthcare provider may recommend a GLP-1 agonist if: Metformin isn’t helping manage T2D. It’s unsafe for you to take metformin (you have a contraindication). You have an A1C that’s higher than your target. You haven’t reached your target A1C within three months of treatment and you have additional conditions, like atherosclerosis, heart failure or chronic kidney disease. It’s important to remember that the most effective management of T2D involves several therapies, like: Lifestyle and diet modifications. Exercise. Medications. Together, you and your healthcare provider will determine a treatment plan that works best for you. Providers often prescribe GLP-1 agonists with other medications to achieve the best blood glucose management. Can I take a GLP-1 agonist if I have Type 1 diabetes? Researchers are currently studying the safety and effectiveness of GLP-1 agonists for people with Type 1 diabetes (T1D). So far, some studies show that these medications can help lower A1C and help with weight loss in people with T1D. The FDA hasn’t approved GLP-1 agonists for the treatment of T1D. But some healthcare providers prescribe it off-label. Talk to your provider to see if this is an option for you. GLP-1 agonists for obesity The FDA currently approves the use of semaglutide and high-dose liraglutide to help treat obesity. This is because these GLP-1 agonists have weight loss effects. Obesity is a chronic condition in which you have a body mass index (BMI) of 30 or higher. Healthcare providers may also prescribe semaglutide or high-dose liraglutide for people who have overweight along with other health conditions if losing weight can help manage the coexisting conditions. Overweight is when you have a BMI of 25 to 29.9. Obesity is a complex condition. Effective management often requires several therapies, like: Dietary changes. Exercise. Medications. Behavior modification programs. Bariatric (weight loss) surgery. If you have obesity or overweight, talk to your healthcare provider to see if a GLP-1 agonist is right for you. Treatment Details How often do you take GLP-1 agonists? Your healthcare provider will tell you when and how often to take your medication (usually injections). Be sure to follow their instructions. But, in general, the frequencies of the injections are: Dulaglutide: Once a week. Exenatide: Twice a day. Exenatide extended-release: Once a week. Liraglutide: Once a day. Lixisenatide: Once a day. Semaglutide: Once a week. Tirzepatide: Once a week. Semaglutide tablets are a daily medication. Risks / Benefits What are the potential benefits of GLP-1 agonists? Other than lowering blood sugar levels and reducing weight, studies show that GLP-1 agonists may have other potential benefits, like: Lowering blood pressure. Improving lipid disorders. Improving fatty liver disease. Reducing your risk of heart disease and kidney disease. Delaying the progression of diabetes-related nephropathy. What are the side effects of GLP-1 agonists? The most common side effects of GLP-1 agonists include: Loss of appetite. Nausea. Vomiting. Diarrhea. These side effects are more likely to happen when you start the medication or if you’re taking an increased dose. Other side effects can include: Dizziness. Mild tachycardia (increased heart rate). Infections. Headaches. Indigestion (upset stomach). You may also have temporary mild itchiness and/or redness on your skin at the site of the injections. Severe — but rare — side effects can include: Pancreatitis. Medullary thyroid cancer. Acute (sudden) kidney injury. Worsening diabetes-related retinopathy. What are the risks or complications of GLP-1 agonists? GLP-1 agonists are generally safe. But there are a few risks to consider, including: Allergic reactions. Use during pregnancy. Low blood sugar (hypoglycemia). GLP-1 agonists and allergic reactions Some people form antibodies to GLP-1 agonists, particularly with exenatide. This can cause issues with the effectiveness of the medication. But it can also cause allergic reactions at the injection site and potentially anaphylaxis, a severe allergic reaction. If you notice persistent itchiness, redness or other symptoms of an allergic reaction at injection sites, talk to your healthcare provider. If you have symptoms of anaphylaxis, call 911 or get to the nearest emergency room. Symptoms of anaphylaxis include: Shortness of breath or wheezing. Hives. Difficulty swallowing. Red rash. Abdominal (belly) pain. Chest tightness. A feeling of doom or dread. GLP-1 agonists and pregnancy GLP-1 agonists aren’t safe to take during pregnancy. Animal studies show that these medications cause developmental abnormalities in the fetus. If you’re able to become pregnant, you should use effective and reliable birth control while taking a GLP-1 agonist. If you become pregnant while taking the medication, see your healthcare provider immediately. GLP-1 agonists and hypoglycemia There’s a low risk of mild low blood sugar (hypoglycemia) episodes if you take a GLP-1 agonist. It can become a serious risk if you take GLP-1s with other medications that lower blood sugar, like sulfonylureas or insulin. Hypoglycemia is blood sugar that’s lower than 70 mg/dL. Without proper treatment, severe hypoglycemia can be life-threatening. Hypoglycemia symptoms include: Shaking or trembling. Sweating and chills. Dizziness or lightheadedness. Weakness. Faster heart rate. Intense hunger (hyperphagia). Difficulty thinking and concentrating. Pale skin (pallor). Nausea. To treat hypoglycemia, you need to consume sugar or carbohydrates, like half a banana or half a cup of apple juice.
ChatGPT said:
ChatGPT

GLP-1 agonists are a class of medications designed to mimic the hormone glucagon-like peptide-1 (GLP-1), which plays a significant role in managing blood sugar levels, regulating appetite, and promoting weight loss. These drugs are primarily used to treat Type 2 diabetes and obesity, with growing evidence showing their effectiveness in both conditions.

How GLP-1 Agonists Work:

  1. Enhance insulin secretion: GLP-1 agonists help the pancreas produce more insulin, especially after eating, which helps lower blood sugar.
  2. Inhibit glucagon release: They suppress the release of glucagon, a hormone that raises blood sugar levels, preventing further glucose production by the liver.
  3. Slow gastric emptying: They delay the emptying of the stomach, which helps reduce blood sugar spikes after meals and increases feelings of fullness.
  4. Promote satiety: By acting on brain regions that regulate hunger and satiety, GLP-1 agonists help reduce appetite and caloric intake, which contributes to weight loss.

Available GLP-1 Agonists:

Some of the GLP-1 agonists currently available in the U.S. market include:

  • Dulaglutide (Trulicity®) – weekly injection.
  • Exenatide (Byetta®) – twice-daily injection.
  • Exenatide extended-release (Bydureon®) – weekly injection.
  • Liraglutide (Victoza®) – daily injection.
  • Lixisenatide (Adlyxin®) – daily injection.
  • Semaglutide injection (Ozempic®) – weekly injection.
  • Semaglutide tablets (Rybelsus®) – daily oral medication.

Benefits of GLP-1 Agonists:

  • Blood sugar control: Especially in people with Type 2 diabetes, these medications improve blood sugar levels.
  • Weight loss: They are effective for managing obesity by reducing appetite and food intake.
  • Cardiovascular benefits: Some GLP-1 agonists (like liraglutide and semaglutide) have been shown to reduce the risk of cardiovascular events in people with Type 2 diabetes and heart disease.
  • Potential additional benefits: They may help lower blood pressure, improve cholesterol levels, and reduce fatty liver disease.

Side Effects and Risks:

Common side effects include:

  • Nausea, vomiting, diarrhea.
  • Loss of appetite.
  • Injection site reactions (for injectable versions).

More severe but rare risks include:

  • Pancreatitis.
  • Thyroid tumors (in animal studies).
  • Hypoglycemia (low blood sugar), especially when combined with other diabetes medications.
  • Kidney injury.

Special Considerations:

  • Not safe during pregnancy: GLP-1 agonists are not recommended for pregnant women due to the risk of developmental abnormalities.
  • Injection frequency: Most GLP-1 agonists are injected, with varying frequencies from daily to weekly, depending on the specific medication.

These medications offer a promising approach for people with Type 2 diabetes and obesity, especially when combined with other lifestyle modifications like diet and exercise.

Explore More on GLP-1 and Weight Management

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *